The risk of relapse after a clinically isolated syndrome is related to the pattern of oligoclonal bands

Journal of Neuroimmunology

Volumn 226, Issue 1-2, 2010, Pages 143-146

  Bosca I ^a   Magraner, M J ^a   Coret, F ^b   Alvarez Cermeno J C ^c   Simo Castello M ^a   Villar, L M ^c   Casanova, B ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Clinically isolated syndrome; IgG oligoclonal bands; IgM oligoclonal bands; MRI; Multiple sclerosis

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; OLIGOCLONAL BAND;

ADULT; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL TRIAL; CLINICALLY ISOLATED SYNDROME; COHORT ANALYSIS; CONTROLLED STUDY; DEMYELINATING DISEASE; DIAGNOSTIC VALUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE RISK; SPAIN; ANALYSIS OF VARIANCE; BLOOD; CEREBROSPINAL FLUID; IMMUNOLOGY; KAPLAN MEIER METHOD; LONGITUDINAL STUDY; METABOLISM; MORTALITY; PATHOLOGY; PROCEDURES; RECURRENT DISEASE; RISK FACTOR; YOUNG ADULT;

ADULT; ANALYSIS OF VARIANCE; DEMYELINATING DISEASES; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; KAPLAN-MEIERS ESTIMATE; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; OLIGOCLONAL BANDS; RECURRENCE; RISK FACTORS; YOUNG ADULT; KAPLAN-MEIER ESTIMATE;

EID: 77956343443     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2010.05.032     Document Type: Article

References (36)

1. Andersson M., Álvarez-Cermeño J., Bernardi G., Cogato I., Fredman P., Frederiksen J., Fredrikson S., Gallo P., Grimaldi L.M., Gronning M., et al. Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J. Neurol. Neurosurg. Psychiatry 1994, 57:897-902.
2. Barkhof F., Filippi M., Miller D.H., Scheltens P., Campi A., Polman C.H., Comi G., Ader H.J., Losseff N., Valk J. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997, 120:2059-2069.
3. Boes M. Role of natural and immune IgM antibodies in immune responses. Mol. Immunol. 2000, 37:1141-1149.
4. Bongioanni P., Fioretti C., Vanacore R., Bianchi F., Lombardo F., Ambrogi F., Meucci G. Lymphocyte subsets in multiple sclerosis. A study with two-colour fluorescence analysis. J Neurol Sci 1996, 139:71-77.
5. Brex P.A., Ciccarelli O., O'Ríordan J.I., Sailer M., Thompson A.J., Miller D.H. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J. Med. 2002, 346:158-164.
6. Comi G., Filippi M., Barkhof F., Durelli L., Edan G., Fernandez O., Hartung H., Seeldrayers P., Sorensen P.S., Rovaris M., Martinelli V., Hommes O.R. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001, 357:1576-1582.
7. Comi G., Martinelli V., Rodegher M., Moiola L., Bajenaru O., Carra A., Elovaara I., Fazekas F., Hartung H.P., Hillert J., King J., Komoly S., Lubetzki C., Montalbán X., Myhr K.M., Ravnborg M., Rieckmann P., Wynn D., Young C., Filippi M. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009, 374:1503-1511.
8. Confavreux C., Aimard G., Devic M. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain 1980, 103:281-300.
9. Confavreux C., Vukusic S., Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 2003, 126:770-782.
10. Duan B., Morel L. Role of B-1a cells in autoimmunity. Autoimmun. Rev. 2006, 5:403-408.
11. Fisniku L.K., Brex P.A., Altmann D.R., Miszkiel K.A., Benton C.E., Lanyon R., Thompson A.J., Miller D.H. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008, 131:808-817.
12. Frohman E.M., Havrdova E., Lublin F., Barkhof F., Achiron A., Sharief M.K., Stüve O., Racke M.K., Steinman L., Weiner H., Olek M., Zivadinov R., Corboy J., Raine C., Cutter G., Richert J., Filippi M. Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis. Arch. Neurol. 2006, 63:614-619.
13. Giovannoni G., Kieseier B., Hartung H.P. Correlating immunological and magnetic resonance imaging markers of disease activity in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 1998, 64(Suppl 1):S31-S36.
14. Jacobs L.D., Beck R.W., Simon J.H., Kinkel R.P., Brownscheidle C.M., Murray T.J., Simonian N.A., Slasor P.J., Sandrock A.W. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000, 343:898-904.
15. Jin Y.P., de Pedro-Cuesta J., Huang Y.H., Söderström M. Predicting multiple sclerosis at optic neuritis onset. Mult. Scler. 2003, 9:135-141.
16. Kappos L., Polman C.H., Freedman M.S., Edan G., Hartung H.P., Miller D.H., Montalbán X., Barkhof F., Bauer L., Jakobs P., Pohl C., Sandbrink R. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006, 67:1242-1249.
17. Mandrioli J., Sola P., Bedin R., Gambini M., Merelli E. A multifactorial prognostic index in multiple sclerosis. Cerebrospinal fluid IgM oligoclonal bands and clinical features to predict the evolution of the disease. J Neurol 2008, 255:1023-1031.
18. Masjuan J., Álvarez-Cermeño J.C., García-Barragán N., Díaz-Sánchez M., Espiño M., Sádaba M.C., González-Porqué P., Martinez-San Millán J., Villar L.M. Clinically isolated syndromes: a new oligoclonal band test accurately predicts conversion to MS. Neurology 2006, 66:576-578.
19. Mead R.J., Singhrao S.K., Neal J.W., Lassmann H., Morgan B.P. The membrane attack complex of complement causes severe demyelination associated with acute axonal injury. J. Immunol. 2002, 168:458-465.
20. Perini P., Ranzato F., Calabrese M., Battistin L., Gallo P. Intrathecal IgM production at clinical onset correlates with a more severe disease course in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 2006, 77:953-955.
21. Pittock S.J., Weinshenker B.G., Noseworthy J.H., Lucchinetti C.F., Keegan M., Wingerchuk D.M., Carter J., Shuster E., Rodriguez M. Not every patient with multiple sclerosis should be treated at time of diagnosis. Arch. Neurol. 2006, 63:611-614.
22. Poser C.M., Paty D.W., Scheinberg L., McDonald W.I., Davis F.A., Ebers G.C., Johnson K.P., Sibley W.A., Silberberg D.H., Tourtellotte W.W. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 1983, 13:227-231.
23. Rocca M.A., Agosta F., Sormani M.P., Fernando K., Tintoré M., Korteweg T., Tortorella P., Miller D.H., Thompson A., Rovira A., Montalbán X., Polman C., Barkhof F., Filippi M. A three-year, multi-parametric MRI study in patients at presentation with CIS. J. Neurol. 2008, 255:683-691.
24. Sádaba M.C., González Porqué P., Masjuán J., Álvarez-Cermeño J.C., Bootello A., Villar L.M. An ultrasensitive method for the detection of oligoclonal IgG bands. J. Immunol. Meth. 2004, 284:141-145.
25. Schroeder H.W., Cavacini L. Structure and function of immunoglobulins. J. Allergy Clin. Immunol. 2010, 125:S41-S52.
26. Sharief M.K., Thompson E.J. The predictive value of intrathecal immunoglobulin synthesis and magnetic resonance imaging in acute isolated syndromes for subsequent development of multiple sclerosis. Ann. Neurol. 1991, 29:147-151.
27. Thangarajh M., Gómez-Rial J., Hedstrom A.K., Hillert J., Álvarez-Cermeño J.C., Masterman T., Villar L.M. Lipid-specific immunoglobulin M in CSF predicts adverse long-term outcome in multiple sclerosis. Mult. Scler. 2008, 14:1208-1213.
28. Tintoré M., Rovira A., Martinez M.J., Río J., Diaz-Villoslada P., Brieva L., Borrás C., Grive E., Capellades J., Montalbán X. Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. AJNR Am. J. Neuroradiol. 2000, 21:702-706.
29. Tintoré M., Rovira A., Río J., Nos C., Grive E., Téllez N., Pelayo R., Comabella M., Sastre-Garriga J., Montalbán X. Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology 2006, 67:968-972.
30. Tintoré M., Rovira A., Río J., Tur C., Pelayo R., Nos C., Téllez N., Perkal H., Comabella M., Sastre-Garriga J., Montalbán X. Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis?. Neurology 2008, 70:1079-1083.
31. Tourtellotte W.W., Walsh M.J., Baumhefner R.W., Staugaitis S.M., Shapshak P. The current status of multiple sclerosis intra-blood-brain-barrier IgG synthesis. Ann N Y Acad Sci 1984, 436:52-67.
32. Villar L.M., Masjuán J., González-Porqué P., Plaza J., Sádaba M.C., Roldan E., Bootello A., Álvarez-Cermeño J.C. Intrathecal IgM synthesis in neurologic diseases: relationship with disability in MS. Neurology 2002, 58:824-826.
33. Villar L.M., Masjuán J., González-Porqué P., Plaza J., Sádaba M.C., Roldán E., Bootello A., Álvarez-Cermeño J.C. Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS. Neurology 2002, 59:555-559.
34. Villar L.M., Masjuán J., González-Porqué P., Plaza J., Sádaba M.C., Roldan E., Bootello A., Álvarez-Cermeño J.C. Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis. Ann. Neurol. 2003, 53:222-226.
35. Villar L.M., Sádaba M.C., Roldán E., Masjuán J., González-Porqué P., Villarrubia N., Espino M., García-Trujillo J.A., Bootello A., Álvarez-Cermeño J.C. Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. J Clin Invest 2005, 115:187-194.
36. Villar L., García-Barragán N., Espiño M., Roldán E., Sádaba M., Gómez-Rial J., González-Porqué P., Álvarez-Cermeño J. Influence of oligoclonal IgM specificity in multiple sclerosis disease course. Mult. Scler. 2008, 14:183-187.